MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

Search

Simulations Plus Inc

Slēgts

SektorsVeselības aprūpe

16.95 -3.42

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

16.93

Max

17.09

Galvenie mērījumi

By Trading Economics

Ienākumi

2.9M

3.1M

Pārdošana

3.5M

22M

P/E

Sektora vidējais

46.75

39.564

EPS

0.31

Dividenžu ienesīgums

1.38

Peļņas marža

13.704

Darbinieki

243

EBITDA

4.9M

5M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+69.52% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

1.38%

2.40%

Nākamie ieņēmumi

2025. g. 14. jūl.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-136M

357M

Iepriekšējā atvēršanas cena

20.37

Iepriekšējā slēgšanas cena

16.95

Ziņu noskaņojums

By Acuity

50%

50%

131 / 376 Rangs Healthcare

Simulations Plus Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 11. jūl. 22:19 UTC

Iegādes, apvienošanās, pārņemšana

FCC Approves U.S. Cellular Sale to T-Mobile

2025. g. 11. jūl. 17:28 UTC

Galvenie tirgus virzītāji

SharpLink Gaming Gains on Ethereum Purchase

2025. g. 11. jūl. 16:57 UTC

Peļņas

BASF Cuts Outlook on Global Economy Uncertainty

2025. g. 12. jūl. 17:01 UTC

Peļņas

That's a Wrap on Prime Day. What the Numbers Show. -- Barrons.com

2025. g. 12. jūl. 14:53 UTC

Peļņas

That's a Wrap on Prime Day. What the Numbers Show. -- Barrons.com

2025. g. 12. jūl. 02:24 UTC

Iegādes, apvienošanās, pārņemšana

Google to Pay $2.4 Billion in Deal to License Tech of Coding Startup, Hire CEO -- Update

2025. g. 12. jūl. 02:05 UTC

Iegādes, apvienošanās, pārņemšana

Google to Pay $2.4 Billion in Deal to License Tech of Coding Startup, Hire CEO -- WSJ

2025. g. 12. jūl. 02:05 UTC

Iegādes, apvienošanās, pārņemšana

Google to Hire Windsurf CEO and Other Employees, Company Says -- WSJ

2025. g. 12. jūl. 02:05 UTC

Iegādes, apvienošanās, pārņemšana

Google to Pay About $2.4 Billion in Deal to License Tech of AI Coding Startup, Sources Say -- WSJ

2025. g. 11. jūl. 21:45 UTC

Tirgus saruna

Fitch Affirms Germany's Rating, Sees Deficit, Debt Rising -- Market Talk

2025. g. 11. jūl. 19:46 UTC

Iegādes, apvienošanās, pārņemšana

Kraft Heinz Might Split Up, Report Says. What Investors Need to Know. -- Barrons.com

2025. g. 11. jūl. 19:45 UTC

Tirgus saruna

Crude Futures Post Back-to-Back Weekly Gains -- Market Talk

2025. g. 11. jūl. 19:05 UTC

Tirgus saruna

U.S. Natural Gas Futures Post Third Straight Weekly Loss -- Market Talk

2025. g. 11. jūl. 18:18 UTC

Tirgus saruna

Canada Officials Tight-Lipped on Next Steps in Trump Trade Talks -- Market Talk

2025. g. 11. jūl. 17:35 UTC

Tirgus saruna

Canada Should Target Lower Sectoral Tariffs, Import Quotas in US Trade Talks -- Market Talk

2025. g. 11. jūl. 17:26 UTC

Tirgus saruna

U.S. Oil Rig Count Down by 1 to 424 -- Market Talk

2025. g. 11. jūl. 16:53 UTC

Tirgus saruna

Crude Futures Add to Early Gains -- Market Talk

2025. g. 11. jūl. 16:42 UTC

Peļņas

BASF Cuts Outlook on Global Economic Uncertainty

2025. g. 11. jūl. 16:08 UTC

Tirgus saruna

Rise in Canadian Staycations May Help Explain Labor Market Strength -- Market Talk

2025. g. 11. jūl. 16:05 UTC

Peļņas

BASF Will Publish Half-Year Results on July 30

2025. g. 11. jūl. 16:04 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 11. jūl. 16:04 UTC

Tirgus saruna

Senior Housing Shortage Gives REITs Pricing Power -- Market Talk

2025. g. 11. jūl. 16:03 UTC

Peļņas

BASF: Guidance Cut Is Due to Ongoing Macroeconomic, Geopolitical Uncertainties

2025. g. 11. jūl. 16:02 UTC

Peļņas

BASF Continues to Expect Free Cash Flow Between EUR400M and EUR800M in 2025

2025. g. 11. jūl. 16:01 UTC

Peļņas

BASF Had Seen Ebitda Before Special Items Between EUR8B and EUR8.4B in 2025

2025. g. 11. jūl. 16:00 UTC

Peļņas

BASF Now Sees Ebitda Before Special Items Between EUR7.3B and EUR7.7B in 2025

2025. g. 11. jūl. 15:59 UTC

Peļņas

BASF Cuts 2025 Earnings View

2025. g. 11. jūl. 15:58 UTC

Peļņas

Nvidia's CEO Has Sold a Million Shares. He Has Millions More to Sell. -- Barrons.com

2025. g. 11. jūl. 15:57 UTC

Peļņas

BASF 2Q EBIT Before Special Items EUR810M

2025. g. 11. jūl. 15:54 UTC

Peļņas

BASF: Analysts Had Expected 2Q Sales of EUR15.80B

Salīdzinājums

Cenas izmaiņa

Simulations Plus Inc Prognoze

Cenas mērķis

By TipRanks

69.52% augšup

Prognoze 12 mēnešiem

Vidējais 28.75 USD  69.52%

Augstākais 40 USD

Zemākais 22 USD

Pamatojoties uz 7 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Simulations Plus Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

7 ratings

5

Pirkt

2

Turēt

0

Pārdot

Noskaņojums

By Acuity

131 / 376 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.